Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

33.53 -1.94 (-5.46%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
News headline image
HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗
The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs. 
Via Stocktwits
News headline image
The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Why Shares of Novo Nordisk Stock Collapsed This Week ↗
The drugmaker is facing pricing pressures on its weight loss medications. 
Via The Motley Fool
News headline image
Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗
The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs. 
Via Stocktwits
Topics Fraud Law Enforcement
HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗
Via Stocktwits
Novo Nordisk Threatens Legal Action Against Hims & Hers Over Compounded Wegovy Pill ↗
Via Stocktwits
News headline image
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗
There's another fight brewing around GLP-1 drugs -- this time on the delivery side. 
Via The Motley Fool
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
Hims & Hers Takes On Novo Nordisk: What We Know Right Now ↗
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story. 
Via The Motley Fool
HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test ↗
Via Stocktwits
Why Is HIMS Stock Slipping Premarket Today? ↗
Via Stocktwits
Hims & Hers CEO Bets On Personalized Healthcare And AI In 2026 — Wall Street Braces For A Costly Year ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Eli Lilly Stock Just Dropped ↗
Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there. 
Via The Motley Fool
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
Via Stocktwits
Topics Intellectual Property
News headline image
Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*
From Hims & Hers
Via Business Wire
News headline image
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering ↗
Hims & Hers is moving beyond prescriptions to preventative testing. 
Via The Motley Fool
News headline image
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care
From Hims & Hers
Via Business Wire
News headline image
1 Volatile Stock for Long-Term Investors and 2 We Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
News headline image
Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q3 Earnings?
Shareholders of Hims & Hers Health would probably like to forget the past six months even happened. The stock dropped 57.1% and now trades at $27.15. This may have investors wondering how to approach... 
Via StockStory
News headline image
1 Healthcare Stock to Research Further and 2 Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare... 
Via StockStory
Topics Stocks
News headline image
Will Netflix Go All-Cash for WBD? ↗
Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over
From Hims & Hers
Via Business Wire
News headline image
2 Top Stocks to Double Up On Right Now ↗
When you find winning stocks, stick with them. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Hims & Hers Health (HIMS) Stock Is Down Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing... 
Via StockStory
Topics Artificial Intelligence
Nasdaq, S&P 500 Futures Wobble As Trump-Powell Clash Rattles Markets: Why CRML, HIMS, WMT, NFLX, NVAX, COF Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Stocks to Love in 2026 ↗
Are you looking for investment opportunities in 2026? 
Via The Motley Fool
Topics ETFs Initial Public Offering
News headline image
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗
The development comes as attention remains on Hims’ longer-term business expansion initiatives. 
Via Stocktwits
News headline image
1 High-Flying Stock on Our Watchlist and 2 We Question
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and... 
Via MarketMinute
Topics Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.